Search | Clinical Trials Finder

Conditions: Carcinoma, Non-small Cell Lung
Interventions: Tarceva (Erlotinib); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Interventions: Berzosertib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Topotecan Hydrochloride; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 33
States / cities: Los Angeles, California • Newport Beach, California • Sacramento, California + 26 more

Conditions: Non-Small Cell Lung Cancer
Interventions: cis-diamminedichloroplatinum; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Limited Stage Small Cell Lung Cancer
Interventions: Ociperlimab, Tislelizumab, Concurrent Chemoradiotherapy; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Lung Cancer
Interventions: laromustine; Drug
Lead sponsor: Vion Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 9
States / cities: Los Angeles, California • New Haven, Connecticut • West Haven, Connecticut + 6 more

Conditions: Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: Ponatinib; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Lung Cancer
Interventions: radiation therapy; Radiation
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 0 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: NSCLC
Interventions: Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Standard of care neoadjuvant therapy, Surgical Resection; Device · Drug · Other
Lead sponsor: Galvanize Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Lung Cancer, Metastatic Cancer
Interventions: isolated perfusion, paclitaxel, hyperthermia treatment; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: BIBW 2992 (Afatinib); Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous
Interventions: PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 11
States / cities: Huntsville, Alabama • Stanford, California • Athens, Georgia + 5 more

Conditions: Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
Interventions: assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment; Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 113
States / cities: Tucson, Arizona • Castro Valley, California • Duarte, California + 78 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Not listed
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non Small Cell Lung Cancer
Interventions: DCE-MRI scan, Stereotactic Body Radiation Therapy, 4D-CT scan; Other · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Lung Cancer
Interventions: questionnaire administration, computed tomography, radiation therapy treatment planning/simulation; Other · Procedure · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Head and Neck Cancer, Lung Cancer
Interventions: celecoxib, adjuvant therapy; Drug · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 4
States / cities: Chicago, Illinois • Chapel Hill, North Carolina

Conditions: Lung Cancer
Interventions: radiation therapy; Radiation
Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris; Other
Eligibility: Up to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions: Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Drug · Procedure · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 391
States / cities: Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 291 more

Conditions: Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage III Non-small Cell Lung Cancer, Stage I Pancreatic Cancer, Stage II Non-small Cell Lung Cancer, Stage IVB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Colon Cancer, Stage IVA Pancreatic Cancer
Interventions: Detox-B adjuvant, ras peptide cancer vaccine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Timeline: Started 1995
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Pain, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: assessment of therapy complications, cognitive assessment, psychosocial assessment and care; Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 2,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 32
States / cities: Chicago, Illinois • Evanston, Illinois • Elkhart, Indiana + 19 more

Conditions: Lung Cancer
Interventions: radiation therapy-3 fractions, Radiation therapy-5 fractions; Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2034
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Carcinoma, Non-Small-Cell-Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
Interventions: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13, Modified Medical Research Council, EQ-5D, Center for Epidemiological Studies Depression Scale, Medical Outcomes Study Social Support Survey; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Durvalumab, Patient Observation, Questionnaire Administration; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2039
U.S. locations: 279
States / cities: Jonesboro, Arkansas • Beverly Hills, California • Dublin, California + 222 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Recombinant DNA- pVAX/L523S, Recombinant adenovirus- Ad/L523S; Biological
Lead sponsor: Corixa Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 5
States / cities: Ocoee, Florida • Dallas, Texas • Tyler, Texas + 2 more

Search by objective public record fields.

Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Intratumoral Cisplatin for Resectable NSCLC

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

Radiation Therapy in Preventing Brain Metastases in Patients With Small Cell Lung Cancer

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer

Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)

Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors

Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer

Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer

Study Comparing Two Different Schedules of Radiation for Early-stage Lung Cancer

SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer